×

Crush resistant delayed-release dosage forms

  • US 10,675,278 B2
  • Filed: 03/04/2016
  • Issued: 06/09/2020
  • Est. Priority Date: 02/04/2005
  • Status: Active Grant
First Claim
Patent Images

1. A dosage form comprising a physiologically effective amount of a physiologically active substance (A), a polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic, or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N, wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed, wherein the physiologically active substance (A) is the only physiologically active substance within the dosage form, wherein the physiologically active substance (A) consists of oxycodone, a physiologically acceptable salt of oxycodone, or a physiologically acceptable derivative of oxycodone, and wherein the polymer (C) is polyethylene oxide (PEO) having a molecular weight of 500,000 g/mol to 7 million g/mol determined according to rheological measurements.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×